Log In
BCIQ
Print this Print this
 

PSX1050

  Manage Alerts
Collapse Summary General Information
Company Circassia Pharmaceuticals plc
DescriptionFormulation of fluticasone propionate in a pressurized metered dose inhaler (pMDI) with a dose counter
Molecular Target
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$152.7M

$106.9M

$45.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/15/2015

$152.7M

$106.9M

$45.8M

04/21/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today